Aminoglycoside-induced renal phospholipidosis and nephrotoxicity

Biochemical Pharmacology

Volumn 40, Issue 11, 1990, Pages 2383-2392

  Laurent, Guy ^a   Kishore, Bellamkonda K ^a   Tulkens, Paul M ^a  

^a International Institute of Cellular and Molecular Pathology   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; STREPTOMYCIN;

DRUG TRANSPORT; HUMAN; KIDNEY TUBULE NECROSIS; LIPIDOSIS; LYSOSOME; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTIBIOTICS, AMINOGLYCOSIDE; HUMAN; KIDNEY; KIDNEY DISEASES; LIPOIDOSIS; LYSOSOMES; PHOSPHOLIPIDS; SUPPORT, NON-U.S. GOV'T;

EID: 0025646957     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(90)90078-Y     Document Type: Article

References (95)

1. Structure-activity relationships in aminoglycoside-aminocyclitol antibiotics
2. Aminoglycoside research 1975–1985: Prospects for development of improved agents
3. Aminoglycosides and spectinomycin: Aminocyclitols
4. Antimicrobial agents. The aminoglycosides
5. Antibiotic-induced nephrotoxicity
6. Aminoglycoside toxicity: A review of clinical studies published between 1975 and 1982
7. Is aminoglycoside-associated nephrotoxicity uncommon in the U.K.?
8. Mechanisms of aminoglycoside nephrotoxicity
9. What is the cost of nephrotoxicity associated with aminoglycosides?
10. Nephrotoxicity of gentamicin
11. A light and electron microscopic analysis of gentamicin nephrotoxicity in rats
12. Persistence of sisomicin and gentamicin in renal cortex and medulla compared with other organs and serum of rats
13. Recovery of cortical phospholipidosis and necrosis after acute gentamicin loading in rats
14. 3H]gentamicin in the proximal renal tubules of mice
15. Gentamicin incorporation along the nephron Autoradiographic study on isolated tubules
16. Autoradiographic studies of intracellular aminoglycoside disposition in the kidney
17. Autoradiography of tobramycin uptake by the proximal and distal tubules of normal and endotoxin-treated rats
18. Autoradiography of gentamicin uptake by the rat proximal tubule cell
19. Effect of netilmicin on the phospholipid composition of subcellular fractions of rat renal cortex
20. Impairment of lysosomepinocytic vesicle fusion in rat kidney proximal tubules after treatment with gentamicin at low doses
21. Experimental studies on nephrotoxicity of aminoglycosides at low doses: Mechanisms and perspectives
22. Morphological alterations in distal and collecting tubules of the rat renal cortex after aminoglycoside administration at low doses
23. Early effects of gentamicin, tobramycin and amikacin on the human kidney
24. Mechanism of aminoglycoside-induced lysosomal phospholipidosis: In vitro and in vivo studies with gentamicin and amikacin
25. Aminoglycosides induce a phospholipidosis in the renal cortex of the rat: An early manifestation of nephrotoxicity
26. Comparative effects of aminoglycosides on renal cortical and urinary phospholipids in the rat
27. Effect of netilmicin and amikacin on urinary phospholipid excretion in humans
28. Effect of gentamicin on phospholipid metabolism in cultured rabbit proximal tubular cells
29. Gentamicin-induced lysosomal phospholipidosis in cultured rat fibroblasts
30. Comparative toxicity of aminoglycoside antibiotics towards the lysosomes in a cell culture model
31. Effect of gentamicin on sphingomyelinase activity in cultured human renal proximal tubular cells
32. Increased levels of protein- and lipid-bound sialic acids in the renal cortex of rats injected with low doses of gentamicin
33. Identification of the aminoglycoside binding site in renal renal brush border membranes
34. Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides
35. Tobramycin binding to renal brush border membrane is saturable at clinically-relevant concentrations
36. Interaction of aminoglycoside antibiotics with phospholipid liposomes studies by microelectrophoresis
37. Poly-l-aspartic acid (pASP), a protectant against aminoglycoside (AMG)-induced nephrotoxicity, binds gentamicin (GM) in vitro: Possible relevance to in vivo protective action
38. Interactions of aminoglycoside antibiotics with negatively-charged lipid layers: Biochemical and conformational studies
39. Interaction of gentamicin and spermine with bilayer membranes containing negatively charged phospholipids
40. An interaction of aminoglycoside antibiotics with Ca binding to lipid monolayers and to biomembranes
41. Characterization of aminoglycoside-lipid interactions and development of a refined model for ototoxicity testing
42. Interactions of streptomycin and streptomycylamine derivatives with negatively charged lipid layers: Correlation between binding, conformation of complexes and inhibition of phospholipase activities
43. Ultrastructural, physicochemical and conformational study of the interactions of gentamicin and bis(beta-diethylaminoethylether)-hexestrol with negatively-charged phospholipid bilayers
44. Inhibition of lysosomal phospholipases by aminoglycoside antibiotics: Comparative studies in vitro
45. Biochemical mechanism of aminoglycoside-induced inhibition of phosphatidylcholine hydrolysis by lysosomal phospholipases
46. Inhibition of kidney lysosomal phospholipases A and C by aminoglycoside antibiotics: Possible mechanism of aminoglycoside toxicity
47. Effects of acidic phospholipids, nucleotides and heparin on the activity of lipase from rat liver lysosomes
48. Characterization of phosphatidylinositol phospholipase C activity in rat liver lysosomes and of its inhibition by aminoglycoside antibiotics
49. Inhibition of lysosomal sphingomyelinase by incubation with negatively-charged phospholipid vesicles (liposomes)
50. Comparative study of the alterations induced in rat kidney by gentamicin, dibekacin, netilmicin, tobramycin and amikacin at low doses
51. The role of lysosomes in aminoglycosideinduced nephrotoxicity
52. Comparative nephrotoxicity of gentamicin and tobramycin: Pharmacokinetic and clinical studies in 201 patients
53. Aminoglycoside accumulation kinetics in rat renal parenchyma
54. Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers
55. In vitro and in vivo evaluation of the early renal alterations induced by HAPA-gentamicin B (isepamicin)
56. Evaluation of micronomicin nephrotoxic potential in rats at low and high doses
57. +-adenosine triphosphatase by gentamicin
58. Effects of aminoglycosides on proximal tubule brush border membrane phosphatidylinositol-specific phospholipase C
59. Inhibitory effects of gentamicin on renal mitochondrial oxidative phosphorylation
60. Renal mitochondrial integrity during continuous gentamicin treatment
61. Inhibitory effect of gentamicin on glucogenesis from pyruvate, propionate, and lactate in isolated rabbit kidney-cortex tubules
62. Microsomal protein synthesis inhibition An early manifestation of gentamicin nephrotoxicity
63. The pathology of acute renal failure due to interstitial nephritis in man, with comments on the role of interstitial inflammation and sex in gentamicin nephrotoxicity
64. Kidney tissue repair after nephrotoxic injury: Biochemical and morphological characterization
65. Repair of the nephron following injury with mercuric chloride
66. Increased renal DNA synthesis in vivo after administration of low doses of gentamicin to rats
67. Light and electron microscopic characterization of the proliferative response induced by tobramycin in rat kidney cortex
68. Tissue repair in rat kidney cortex during short treatment with aminoglycosides at low doses: A comparative biochemical and morphometric study
69. Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity
70. Polyaspartic acid protects against gentamicin nephrotoxicity in the rat
71. Reduction of gentamicin nephrotoxicity by the concomitant administration of poly-l-aspartic acid and poly-l-asparagine in rats
72. Effect of aminoglycosides and of coadministration of poly-L-aspartic acid on urinary phospholipids excretion in rats: A comparative study
73. Uptake and subcellular distribution of poly-l-aspartic acid, a protectant against aminoglycoside-induced nephrotoxicity, in rat kidney cortex
74. In vitro and in vivo evaluation of poly-l-aspartic (pASP) and poly-l-glutamic (pGLU) acids as protectants against aminoglycoside (AG)-induced nephrotoxicity: Further evidence for a lysosomal site of action
75. In vitro determinants of complexation between polyaspartic acid and aminoglycosides
76. Effect of a transitory ischaemia on the structure-linked latency of rat liver acid phosphatase and β-galactosidase
77. Effect of gentamicin on the lysosomal system of cultured human proximal tubular cells
78. Effects of aminoglycosides on glomerular permeability, tubular reabsorption, and intracellular catabolism of the cationic low-molecular-weight protein lysozyme
79. Drug-induced lysosomal storage disorders
80. Cytoplasmic and membrane effects of aminoglycosides
81. Gentamicin inhibits agonist stimulation of the phosphatidylinositol cascade in primary cultures of rabbit proximal tubular cells and in rat renal cortex
82. Inhibition of gentamicin uptake in rat renal cortex in vivo by aminoglycosides and organic polycations
83. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats
84. Safety and efficacy of aminoglycosides once-a-day: Experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory disease
85. Chronic gentamicin nephrotoxicity: Continued tubular injury with preserved glomerular filtration function
86. A model for prediction of nephrotoxicity in patients treated with aminoglycosides
87. The influence of dosage regimen on experimental gentamicin nephrotoxicity: Dissociation of peak serum levels from renal failure
88. The post-antibiotic effect
89. The influence of tobramycin dosage regimen on nephrotoxicity, ototoxicity and antibacterial efficacy in a rat model of subcutaneous abscess
90. Nephrotoxicity of aminoglycoside antibiotics
91. Comparative low-dose nephrotoxicities of gentamicin, tobramycin and amikacin
92. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin